COVID-19 in rheumatoid arthritis cases: an Iranian referral center experience.


Journal

Clinical rheumatology
ISSN: 1434-9949
Titre abrégé: Clin Rheumatol
Pays: Germany
ID NLM: 8211469

Informations de publication

Date de publication:
Jul 2021
Historique:
received: 18 07 2020
accepted: 12 10 2020
revised: 09 10 2020
pubmed: 22 11 2020
medline: 12 6 2021
entrez: 21 11 2020
Statut: ppublish

Résumé

Coronavirus infections, known as COVID-19, can induce a fatal respiratory system infection and also affect other organs, such as the kidney and heart. The mortality rate has been estimated between 1 and 5% in previous reports; however, the mortality and morbidity can be higher in patients with the immune-deficiency condition. Rheumatoid arthritis (RA) is one of the most rheumatoid disorders, and it is important to report their clinical and paraclinical data when affected with COVID-19. Evidence about their laboratory and radiologic findings is limited. In this case series, 10 cases of chronic and approved rheumatoid arthritis (RA) affected by COVID-19 are presented. Only 40% had dry cough, but myalgia and weakness as the general first presentation of infections was reported in most cases (80%). Gastrointestinal symptoms, including nausea/vomiting, diarrhea, anorexia, and abdominal pain, were reported in 50% of individuals. In blood cell count, 30% of cases had thrombocytopenia, and ESR in all cases was positive. Abnormal CRP and elevated LDH were seen in 90% of cases. In HRCT assessment, all cases had an abnormal parenchymal pattern, and 90% of cases presented the usual pattern of COVID-19 (bilateral multifocal GGO/consolidation). Although it is a limited report, these findings are helpful for comparison of clinical and paraclinical cases in RA cases with normal cases.

Identifiants

pubmed: 33219453
doi: 10.1007/s10067-020-05464-y
pii: 10.1007/s10067-020-05464-y
pmc: PMC7679060
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2979-2984

Références

Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, Xiong W, Yang D, Chen R, Lu F, Lu Y, Liu X, Chen Y, Li X, Li Y, Summah HD, Lin H, Yan J, Zhou M, Lu H, Qu J (2020) COVID-19 with different severities: a multicenter study of clinical features. Am J Respir Crit Care Med 201(11):1380–1388. https://doi.org/10.1164/rccm.202002-0445OC
doi: 10.1164/rccm.202002-0445OC pubmed: 32275452 pmcid: 7258639
Cheng C, Li C, Zhao T, Yue J, Yang F, Yan Y, Liu X (2020) COVID-19 with rheumatic diseases: a report of 5 cases. Clin Rheumatol 39(7):2025–2029. https://doi.org/10.1007/s10067-020-05160-x
doi: 10.1007/s10067-020-05160-x pubmed: 32406001
Song J, Kang S, Choi SW, Seo KW, Lee S, So MW, Lim DH (2020) Coronavirus disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs. Rheumatol Int 40(6):991–995. https://doi.org/10.1007/s00296-020-04584-7
doi: 10.1007/s00296-020-04584-7 pubmed: 32314010
Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C (2020) Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis 79(5):667–668. https://doi.org/10.1136/annrheumdis-2020-217424
doi: 10.1136/annrheumdis-2020-217424 pubmed: 32241793 pmcid: 7211079
Bozzalla Cassione E, Zanframundo G, Biglia A, Codullo V, Montecucco C, Cavagna L (2020 :annrheumdis-2020-217717) COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine. Ann Rheum Dis 79:1382–1383. https://doi.org/10.1136/annrheumdis-2020-217717
doi: 10.1136/annrheumdis-2020-217717 pubmed: 32398281
Ehrenfeld M, Tincani A, Andreoli L, Cattalini M, Greenbaum A, Kanduc D, Alijotas-Reig J, Zinserling V, Semenova N, Amital H, Shoenfeld Y (2020) Covid-19 and autoimmunity. Autoimmun Rev 19(8):102597–102597. https://doi.org/10.1016/j.autrev.2020.102597
doi: 10.1016/j.autrev.2020.102597 pubmed: 32535093 pmcid: 7289100
Zhong J, Shen G, Yang H, Huang A, Chen X, Dong L, Wu B, Zhang A, Su L, Hou X, Song S, Li H, Zhou W, Zhou T, Huang Q, Chu A, Braunstein Z, Rao X, Ye C, Dong L (2020) COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study. Lancet Rheumatol 2(9):e557–e564. https://doi.org/10.1016/s2665-9913(20)30227-7
doi: 10.1016/s2665-9913(20)30227-7 pubmed: 32838309 pmcid: 7333992
Holman N, Knighton P, Kar P, O'Keefe J, Curley M, Weaver A, Barron E, Bakhai C, Khunti K, Wareham NJ, Sattar N, Young B, Valabhji J (2020) Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol. https://doi.org/10.1016/s2213-8587(20)30271-0
Al-Tawfiq JA, Leonardi R, Fasoli G, Rigamonti D (2020) Prevalence and fatality rates of COVID-19: what are the reasons for the wide variations worldwide? Travel Med Infect Dis:101711. https://doi.org/10.1016/j.tmaid.2020.101711
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395(10229):1054–1062. https://doi.org/10.1016/S0140-6736(20)30566-3
doi: 10.1016/S0140-6736(20)30566-3 pubmed: 32171076 pmcid: 32171076
Pope JE (2020) What does the COVID-19 pandemic mean for rheumatology patients? Curr Treatm Opt Rheumatol 6:1–4. https://doi.org/10.1007/s40674-020-00145-y
doi: 10.1007/s40674-020-00145-y
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395(10223):497–506
doi: 10.1016/S0140-6736(20)30183-5
D'Antiga L (2020) Coronaviruses and immunosuppressed patients: the facts during the third epidemic. Liver Transpl 26(6):832–834. https://doi.org/10.1002/lt.25756
doi: 10.1002/lt.25756 pubmed: 32196933
Tannuri U, Tannuri ACA, Cordon MNA, Miyatani HT (2020) Low incidence of COVID-19 in children and adolescent post-liver transplant at a Latin American reference center. Clinics (Sao Paulo, Brazil) 75:e1986. https://doi.org/10.6061/clinics/2020/e1986
Haberman R, Axelrad J, Chen A, Castillo R, Yan D, Izmirly P, Neimann A, Adhikari S, Hudesman D, Scher JU (2020) Covid-19 in immune-mediated inflammatory diseases — case series from New York. N Engl J Med 383:85–88. https://doi.org/10.1056/NEJMc2009567
doi: 10.1056/NEJMc2009567 pubmed: 32348641
Sawalha AH, Zhao M, Coit P, Lu Q (2020) Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients. Clin Immunol 215(108410):8
Yazdanpanah F, Hamblin MR, Rezaei N (2020) The immune system and COVID-19: friend or foe? Life Sci 256:117900. https://doi.org/10.1016/j.lfs.2020.117900
doi: 10.1016/j.lfs.2020.117900 pubmed: 32502542 pmcid: 7266583
Paces J, Strizova Z, Smrz D, Cerny J (2020) COVID-19 and the immune system. Physiol Res 69:379–388
doi: 10.33549/physiolres.934492
Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G (2020) Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med 58(7):1021–1028. https://doi.org/10.1515/cclm-2020-0369
doi: 10.1515/cclm-2020-0369 pubmed: 32286245 pmcid: 32286245
Ye C, Cai S, Shen G, Guan H, Zhou L, Hu Y, Tu W, Chen Y, Yu Y, Wu X, Zhong J, Dong L (2020) Clinical features of rheumatic patients infected with COVID-19 in Wuhan, China. Ann Rheum Dis 22(217627):2020–217627
Zhong J, Tang J, Ye C, Dong L (2020) The immunology of COVID-19: is immune modulation an option for treatment? Lancet Rheumatol 2(7):e428–e436. https://doi.org/10.1016/s2665-9913(20)30120-x
doi: 10.1016/s2665-9913(20)30120-x pubmed: 32835246 pmcid: 7239618
Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M (2020) The cytokine storm in COVID-19: an overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev 53:25–32. https://doi.org/10.1016/j.cytogfr.2020.05.003
doi: 10.1016/j.cytogfr.2020.05.003 pubmed: 32446778 pmcid: 7211650
Al Shareef K, Bakouri M (2020) Cytokine blood filtration responses in COVID-19. Blood Purif:1–9. https://doi.org/10.1159/000508278

Auteurs

Soraya Shadmanfar (S)

Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Faculty of Medicine, Rheumatology Department, Baqiyatallah University of Medical Sciences, Tehran, Iran.

Nematollah Jonaidi-Jafari (N)

Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.

Ramezan Jafari (R)

Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Faculty of Medicine, Radiology Department, Baqiyatallah University of Medical Sciences, Tehran, Iran.

Zeynab Rastgar-Moqaddam (Z)

Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Amin Saburi (A)

Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran. aminsaburi@yahoo.com.
Dr Saburi Radiology & Ultrasound Clinic, Mashhad, Iran. aminsaburi@yahoo.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH